TW263504B - - Google Patents

Info

Publication number
TW263504B
TW263504B TW081106843A TW81106843A TW263504B TW 263504 B TW263504 B TW 263504B TW 081106843 A TW081106843 A TW 081106843A TW 81106843 A TW81106843 A TW 81106843A TW 263504 B TW263504 B TW 263504B
Authority
TW
Taiwan
Application number
TW081106843A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of TW263504B publication Critical patent/TW263504B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW081106843A 1991-10-03 1992-08-29 TW263504B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77128391A 1991-10-03 1991-10-03

Publications (1)

Publication Number Publication Date
TW263504B true TW263504B (zh) 1995-11-21

Family

ID=25091318

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081106843A TW263504B (zh) 1991-10-03 1992-08-29

Country Status (36)

Country Link
US (4) US5574046A (zh)
EP (1) EP0606248B1 (zh)
JP (1) JP2546785B2 (zh)
KR (1) KR0170458B1 (zh)
CN (1) CN1035615C (zh)
AP (1) AP314A (zh)
AT (1) ATE235490T1 (zh)
AU (1) AU667053B2 (zh)
BG (1) BG61727B1 (zh)
BR (1) BR9206577A (zh)
CA (1) CA2119647C (zh)
CZ (1) CZ290807B6 (zh)
DE (2) DE9290112U1 (zh)
DK (1) DK0606248T3 (zh)
EG (1) EG21481A (zh)
ES (1) ES2193137T3 (zh)
FI (1) FI116939B (zh)
HU (1) HU225049B1 (zh)
IL (1) IL103274A (zh)
IS (1) IS1745B (zh)
MA (1) MA22672A1 (zh)
MX (1) MX9205678A (zh)
NO (1) NO308533B1 (zh)
NZ (1) NZ244601A (zh)
OA (1) OA09895A (zh)
PH (1) PH31290A (zh)
PL (3) PL171984B1 (zh)
PT (1) PT100917B (zh)
RO (1) RO112868B1 (zh)
RU (1) RU2100357C1 (zh)
SG (1) SG52618A1 (zh)
TW (1) TW263504B (zh)
UA (1) UA41290C2 (zh)
UY (1) UY23484A1 (zh)
WO (1) WO1993007140A1 (zh)
ZA (1) ZA927589B (zh)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620973A (en) * 1993-11-30 1997-04-15 Takeda Chemical Industries, Ltd. Tetracyclic condensed heterocyclic compounds and their use
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
KR100639543B1 (ko) 1998-09-30 2006-10-31 다케다 야쿠힌 고교 가부시키가이샤 방광 배출력 개선제
CN1317276C (zh) * 2000-09-29 2007-05-23 中国科学院上海药物研究所 一类吲哚基哌啶类化合物及其制备方法和用途
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
US20050215614A1 (en) * 2002-10-15 2005-09-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
CA2566204A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor
EP1600447A1 (en) * 2004-05-28 2005-11-30 Neuropharma S.A.U. Butyrylcholinesterase selective inhibitors
PE20060430A1 (es) 2004-06-09 2006-05-25 Glaxo Group Ltd Derivados de pirrolopiridina como moduladores de los receptores cannabinoides
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
CN1808106B (zh) * 2005-01-21 2010-11-24 中国科学院上海药物研究所 一种用核磁共振筛选乙酰胆碱酯酶抑制剂的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2324126B1 (en) 2008-08-12 2014-04-23 Zinfandel Pharmaceuticals, Inc. METHOD OF IDENTIFYING Alzheimer's DISEASE RISK FACTORS
CN101503414B (zh) * 2009-03-04 2013-10-30 沈阳药科大学 噻唑并[3,2-b]-1,2,4-三嗪衍生物及其应用
NO2482815T3 (zh) 2009-10-02 2018-09-29
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
MX355479B (es) 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Metodos y productos de farmaco para tratar enfermedad de alzheimer.
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US20150376161A1 (en) 2013-01-29 2015-12-31 Avexxin As Antiiflammatory and antitumor 2-oxothiazoles abd 2-oxothiophenes compounds
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103333163A (zh) * 2013-07-09 2013-10-02 广州中医药大学 一种苯并呋喃类衍生物及其制备方法和应用
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CN107141266B (zh) * 2017-06-28 2019-04-09 佳木斯大学附属第一医院 一种用于治疗阿尔茨海默病的杂环化合物及其制备方法
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL100127C (zh) * 1954-04-28
FR2334358A1 (fr) * 1975-12-12 1977-07-08 Sogeras Nouveaux medicaments derives de l'indole
US4122265A (en) * 1976-05-21 1978-10-24 Hoffmann-La Roche Inc. Derivatives of 3-phenylisoindole-1-carboxylic acid
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
GB8615562D0 (en) * 1986-06-25 1986-07-30 Maggioni Farma Aminoalcohols
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
JP2969359B2 (ja) * 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
US5064840A (en) * 1989-08-03 1991-11-12 Merrell Dow Pharmaceuticals Anti-psychotic piperidylbenzimidazole compounds
TW197442B (zh) * 1990-02-08 1993-01-01 Pfizer
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
TW197435B (zh) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
NZ249286A (en) * 1992-02-13 1996-02-27 Merrell Dow Pharma Piperidine-4-ylmethyl thiophene and thiazole derivatives and pharmaceutical compositions
TW226019B (zh) * 1992-03-23 1994-07-01 Sankyo Co

Also Published As

Publication number Publication date
PL171669B1 (en) 1997-06-30
CZ290807B6 (cs) 2002-10-16
UY23484A1 (es) 1993-03-11
ES2193137T3 (es) 2003-11-01
NO308533B1 (no) 2000-09-25
DE69232976T2 (de) 2003-10-02
PT100917A (pt) 1993-11-30
OA09895A (en) 1995-09-15
JP2546785B2 (ja) 1996-10-23
US6303633B1 (en) 2001-10-16
ATE235490T1 (de) 2003-04-15
DE9290112U1 (de) 1994-06-01
MX9205678A (es) 1993-04-01
AP9200421A0 (en) 1992-10-31
AU667053B2 (en) 1996-03-07
NO941179D0 (no) 1994-03-30
JPH06510788A (ja) 1994-12-01
DK0606248T3 (da) 2003-06-23
HU9400952D0 (en) 1994-06-28
FI941518A (fi) 1994-03-31
EP0606248B1 (en) 2003-03-26
IS3919A (is) 1993-04-04
BG98689A (bg) 1995-03-31
CZ78594A3 (en) 1995-07-12
HUT70544A (en) 1995-10-30
CA2119647A1 (en) 1993-04-15
SG52618A1 (en) 1998-09-28
PT100917B (pt) 1999-07-30
BR9206577A (pt) 1995-10-10
AP314A (en) 1994-02-04
ZA927589B (en) 1994-04-05
KR0170458B1 (ko) 1999-02-18
EG21481A (en) 2001-11-28
CN1035615C (zh) 1997-08-13
WO1993007140A1 (en) 1993-04-15
IL103274A0 (en) 1993-02-21
CA2119647C (en) 1998-08-04
PL171984B1 (pl) 1997-07-31
CN1071166A (zh) 1993-04-21
US6124321A (en) 2000-09-26
NZ244601A (en) 1995-03-28
FI116939B (fi) 2006-04-13
DE69232976D1 (de) 2003-04-30
FI941518A0 (fi) 1994-03-31
IL103274A (en) 1996-11-14
PH31290A (en) 1998-07-06
IS1745B (is) 2000-05-18
US20020049210A1 (en) 2002-04-25
US5574046A (en) 1996-11-12
HU225049B1 (en) 2006-05-29
EP0606248A1 (en) 1994-07-20
BG61727B1 (bg) 1998-04-30
UA41290C2 (uk) 2001-09-17
NO941179L (no) 1994-03-30
AU2519692A (en) 1993-05-03
MA22672A1 (fr) 1993-07-01
RO112868B1 (ro) 1998-01-30
PL171693B1 (pl) 1997-06-30
RU2100357C1 (ru) 1997-12-27

Similar Documents

Publication Publication Date Title
TW263504B (zh)
DE9103004U1 (zh)
DE9102092U1 (zh)
DE9102748U1 (zh)
DE9100936U1 (zh)
DE9102817U1 (zh)
DE9102314U1 (zh)
DE9101024U1 (zh)
DE9101802U1 (zh)
DE9101850U1 (zh)
DE9102355U1 (zh)
DE9102035U1 (zh)
DE9101125U1 (zh)
DE9101777U1 (zh)
DE9101743U1 (zh)
DE9102098U1 (zh)
DE9102845U1 (zh)
DE9100980U1 (zh)
DE9101665U1 (zh)
DE9101424U1 (zh)
DE9103216U1 (zh)
DE9101846U1 (zh)
DE9100108U1 (zh)
DE9100251U1 (zh)
DE9102878U1 (zh)